Skip to content

HAPUSHADI YAPANA BASTI WITH ORAL UPTAKE OF SARASWATA GHRITA IN THE MANAGEMENT OF SPASTIC CEREBRAL PALSY

EFFICACY OF HAPUSHADI YAPANA BASTI WITH ORAL ADMINISTRATION OF SARASWATA GHRITA IN THE MANAGEMENT OF SPASTIC CEREBRAL PALSY- A SINGLE ARM OPEN LABEL CLINICAL TRIAL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/041277
Enrollment
30
Registered
2022-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G809- Cerebral palsy, unspecified

Interventions

None listed

Sponsors

All India Institute Of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age group of 1 to 10 years of either gender. 2)Diagnosed Case of Spastic Cerebral palsy. 3) Parents submitting written consent to participate in this current study.

Exclusion criteria

Exclusion criteria: 1)Progressive neurological disorder. 2) Children suffering from any systemic illness. 3)Children with severe intractable epilepsy as co-morbidity. 4)Acute illness that would interfere with carrying out the interventions. 5)Recent orthopedic surgery/casting/splint. 6)Children had received botox (last 1yr) or had undergone phenol block injection or intrathecal baclofen medication. 7)Fixed contractures. 8)Congenital disorders like Down’s syndrome, Fragile -X syndrome or any congenital anomalies. 9)Caregiver not willing to sign the informed consent form

Design outcomes

Primary

MeasureTime frame
1.Response in improvement of spasticity scale and range of motionTimepoint: 0 day, after completion of treatment i.e. 2 months, and during follow up

Secondary

MeasureTime frame
1.Response in improvement in Quality of life scale 2.Response in improvement in drooling severity and frequency scale 3.Response in improvement in Viking speech scale Timepoint: 0 day, after completion of treatment i.e. 2 months, and during follow up

Countries

India

Contacts

Public ContactDr Rajagopala S

All India Institute Of Ayurveda

srajagopala@gmail.com7600902564

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026